366 employees
ImmunoGen engages in the research and development of antibody-based anticancer therapeutics using its targeted antibody payload technology.
1981
$75M
from 1 investors over 1 rounds
ImmunoGen, Inc. raised $75M on April 6, 2023
Investors: Pharmakon Advisors, LP